
RealRate

PHARMACEUTICAL 2022

LIXTE BIOTECHNOLOGY HOLDINGS INC.

Rank 446 of 475



RealRate

PHARMACEUTICAL 2022

LIXTE BIOTECHNOLOGY HOLDINGS INC.

Rank 446 of 475

The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 29% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Net Income, reducing the Economic Capital Ratio by 534% points.

The company's Economic Capital Ratio, given in the ranking table, is -817%, being 541% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	5,093
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	303
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	2,060
Other Liabilities	0
Other Net Income	-0.54
Property and Equipment	0
Research and Development	1,737
Revenues	0
Selling, General and Administrative Expense	2,931

Output Variable	Value in 1000 USD
Assets	5,093
Liabilities	303
Expenses	6,728
Stockholders Equity	4,790
Net Income	-6,728
Comprehensive Net Income	-6,728
Economic Capital Ratio	-817%